All In Biotech

Drug Trial Radar · NCT06147570

A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

A Phase II, Open-label, Multicenter Study to Evaluate the Efficacy,Safety and Pharmacokinetics of HS-10365 as First-Line Treatment for Patients With Locally Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Sep 25, 2023

Primary completion

Aug 31, 2027

Study completion Aug 31, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the efficacy and safety of HS-10365 in Chinese advanced RET fusion-positive non-small cell lung cancer patients without any systemic therapy.

Conditions

  • Nonsmall Cell Lung Cancer

Interventions

  • HS-10365 capsulesDrug

    HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR assessed by IRCTime frame: From the date of first occurrence of complete response (CR) or partial response (PR) on 2 consecutive occasions (≥4 weeks), until the date of disease progression or withdrawal from study, whichever came first, up to 48 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.